Clinical Trials
16,316 trialsNCT00600496 2026-05-27
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Completed
NCT02159755 2026-05-27
Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02959463 2026-05-27
Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03388619 2026-05-27
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03611595 2026-05-27
Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
University of California, San Diego
Phase 1 Completed
NCT03798678 2026-05-27
CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04958239 2026-05-27
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT04975152 2026-05-27
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT05068102 2026-05-27
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT05176483 2026-05-27
STELLAR-002
Exelixis
Phase 1 Recruiting
NCT05249426 2026-05-27
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT05264974 2026-05-27
Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization
University of Florida
Phase 1 Suspended
NCT05353530 2026-05-27
IMPACT
University of Florida
Phase 1 Recruiting
NCT05806814 2026-05-27
OU-SCC-EXCITE
University of Oklahoma
Phase 1 Active not recruiting
NCT05839626 2026-05-27
A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
Sanofi
Phase 1 Terminated
NCT05870579 2026-05-27
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
Novartis
Phase 1 Recruiting
NCT06077500 2026-05-27
DAREONᵀᴹ-8
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT06120283 2026-05-27
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06132113 2026-05-27
DAREONâ„¢-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
Boehringer Ingelheim
Phase 1 Recruiting
NCT06141031 2026-05-27
Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
Washington University School of Medicine
Phase 1 Recruiting
NCT06177171 2026-05-27
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
University of California, San Francisco
Phase 1 Recruiting
NCT06248411 2026-05-27
A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
Kyowa Kirin Co., Ltd.
Phase 1 Recruiting
NCT06254326 2026-05-27
ADAGiO
University of Florida
Phase 1 Recruiting
NCT06458712 2026-05-27
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Duke Street Bio Ltd
Phase 1 Recruiting
NCT06465316 2026-05-27
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06487481 2026-05-27
Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT06496568 2026-05-27
A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers
Hoffmann-La Roche
Phase 1 Active not recruiting
NCT06619873 2026-05-27
A Clinical Study to Evaluate the Relative Bioavailability and Food Effect of HRS-8080 in Healthy Subjects
Shandong Suncadia Medicine Co., Ltd.
Phase 1 Completed
NCT06714591 2026-05-27
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
SystImmune Inc.
Phase 1 Recruiting
NCT06880549 2026-05-27
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
ModernaTX, Inc.
Phase 1 Active not recruiting
NCT06904066 2026-05-27
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT06914479 2026-05-27
Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors
University of Michigan Rogel Cancer Center
Phase 1 Recruiting
NCT06958939 2026-05-27
The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis
Tang-Du Hospital
Phase 1 Active not recruiting
NCT07012044 2026-05-27
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT07073547 2026-05-27
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
AstraZeneca
Phase 1 Recruiting
NCT07137416 2026-05-27
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT07171203 2026-05-27
Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor
University of California, San Diego
Phase 1 Recruiting
NCT07226349 2026-05-27
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07306559 2026-05-27
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
Boehringer Ingelheim
Phase 1 Recruiting
NCT07407504 2026-05-27
GenSci145 as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors.
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT07414836 2026-05-27
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07438782 2026-05-27
First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Recruiting
NCT07464951 2026-05-27
CART123
Children's Hospital of Philadelphia
Phase 1 Recruiting
NCT07509034 2026-05-27
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
National Institutes of Health Clinical Center (CC)
Phase 1 Not yet recruiting
NCT07541391 2026-05-27
KOALA
Peter MacCallum Cancer Centre, Australia
Phase 1 Recruiting
NCT07572136 2026-05-27
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)
National Institutes of Health Clinical Center (CC)
Phase 1 Not yet recruiting
NCT07603505 2026-05-27
NAE-PCOS
Jinnah Sindh Medical University
Phase 1 Recruiting
NCT07604571 2026-05-27
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
Novartis
Phase 1 Recruiting
NCT07607678 2026-05-27
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab
Boehringer Ingelheim
Phase 1 Recruiting
NCT07608627 2026-05-27
64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer
City of Hope Medical Center
Phase 1 Not yet recruiting